Patents by Inventor Hidehito Yasukawa

Hidehito Yasukawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210252112
    Abstract: An aqueous preparation containing a protein as an active ingredient which is stable in storage in solution and makes an injection pain reduced is provided. More specifically an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM and a protein as an active ingredient is provided. Further more specifically provided is an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM, human growth hormone as an active ingredient, a poloxamer as a non-ionic surfactant; and phenol as a isotonic agent.
    Type: Application
    Filed: June 25, 2019
    Publication date: August 19, 2021
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hidehito YASUKAWA, Takashi HANADA, Junya TANI, Shinji OKABE, Yuuka ASANO
  • Publication number: 20210187082
    Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.
    Type: Application
    Filed: February 22, 2021
    Publication date: June 24, 2021
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hidehito Yasukawa, Yuka Yamaguchi, Shinji Okabe
  • Patent number: 10940185
    Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: March 9, 2021
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hidehito Yasukawa, Yuka Yamaguchi, Shinji Okabe
  • Publication number: 20210061918
    Abstract: Aqueous pharmaceutical compositions containing a fusion protein of an antibody and a lysosomal enzyme as an active ingredient, which are stable enough to be marketed, are disclosed. The aqueous pharmaceutical composition, for example, comprises the fusion protein of the antibody and the lysosomal enzyme at a concentration of 0.5 to 20 mg/mL, sodium chloride at a concentration of 0.3 to 1.2 mg/mL, sucrose at a concentration of 50 to 100 mg/mL, a nonionic surfactant at a concentration of 0.15 to 3 mg/mL, a buffer at a concentration of 3 to 30 mM, and is adjusted to pH 5.0 to 7.5.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 4, 2021
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hidehito YASUKAWA, Yuka YAMAGUCHI, Shinji OKABE
  • Publication number: 20190336586
    Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.
    Type: Application
    Filed: December 28, 2017
    Publication date: November 7, 2019
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hidehito Yasukawa, Yuka Yamaguchi, Shinji Okabe